FDA’s Busiest Advisory Committee
This article was originally published in RPM Report
The Anesthetic & Analgesic Drug Products Advisory Committee is scheduled for five days of meetings in the coming months – and FDA’s revised policy on opioids suggests that panel will be meeting a lot more often in the years to come.
You may also be interested in...
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.